|
業務類別
|
-- |
|
業務概覽
|
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease). |
| 公司地址
| Allee de la Recherche, 60, Brussels, BEL, B-1070 |
| 電話號碼
| +32 25599999 |
| 傳真號碼
| +32 25599900 |
| 公司網頁
| https://www.ucb.com |
| 員工數量
| 10117 |
| Mr. Jean-Christophe Tellier |
Director and Chief Executive Officer |
-- |
25/02/2026 |
|
|
| Mr. Ulf Wiinberg |
Independent Director |
25/02/2026 |
| Mr. Stef Heylen |
Independent Director |
25/02/2026 |
| Mr. Jonathan M. Peacock |
Chairman of the Board |
25/02/2026 |
| Mr. Jean-Christophe Tellier |
Director and Chief Executive Officer |
25/02/2026 |
| Ms. Fiona Powrie |
Independent Director |
25/02/2026 |
| Ms. Nefertiti Greene |
Independent Director |
25/02/2026 |
| Dr. Jan Berger |
Independent Director |
25/02/2026 |
| Dr. Dolca Thomas, M.D. |
Independent Director |
25/02/2026 |
| Ms. Maelys Castella |
Independent Director |
25/02/2026 |
| Ms. Kay Davies |
Independent Director |
25/02/2026 |
| Mr. Pierre L. Gurdjian |
Independent Director |
25/02/2026 |
| Mr. Charles-Antoine Janssen |
Vice Chairman of the Board |
25/02/2026 |
| Mr. Cedric van Rijckevorsel |
Director |
25/02/2026 |
| Mr. Rodolfo J. Savitzky |
Independent Director |
25/02/2026 |
| Mr. Cyril Janssen |
Director |
25/02/2026 |
|
|
|
|
